Ovarian Cancer Patients Treated with Combo Veliparib Plus Chemotherapy
A trial analyzed the efficacy of veliparib as an add-on to first-line induction chemotherapy with carboplatin and paclitaxel in ovarian cancer patients.
Related Articles
FDA Approves the First and Only Monotherapy for Treatment-Resistant Depression | Docwire News
The FDA approved esketamine nasal spray for the treatment of adults living with major depressive disorder who have not responded to at least two oral…
New Risk Stratification Method for Cervical Cancer | Docwire News
Results were deduced from self-collected as well as clinician-obtained screening results.
New Drug for IBD Designed Using Generative AI | Docwire News
The early discovery of the preclinical candidate nomination took only 12 months.
Coronary Sinus Reducer Shows Promise for Coronary Microvascular Dysfunction | Docwire News
Dr. Amit Goyal details a study which explored the role of coronary sinus reducer in Coronary microvascular dysfunction.
KATHERINE Study: Trastuzumab Emtansine Enhances Survival in HER2 Breast Cancer | Docwire News
In patients with high-risk HER2-psoitive breast cancer, adjuvant trastuzumab emtansine reduces the long-term risk of death.
Correlation Between Breast Cancer Diagnosis Stage and Prevalence of Heart Disease | Docwire News
The study used SEER data of nearly 20,000 cases.
Association Between T2D, CVD and Sugary Drinks Is Prominent Around Globe | Docwire News
Estimates show that 2.2 million new cases of T2D and 1.2 million new cases of CVD are associated with sugary beverages.
Evaluation of Selenoprotein Gene Expression as Prognostic Marker for Ovarian Cancer | Docwire News
A team of researchers aimed to analyze the genetic expression and prognostic value of selenoprotein gene mutations.
Cost-Related Nonadherence in Asthma Still Prevalent Despite Lowering Rates of Disease | Docwire News
Asthma therapy cost is still a barrier for some.
A Novel Tool is Effective at Predicting the Onset of Mild Cognitive Impairment and AD | Docwire News
A new model called the Florey Dementia Index (FDI) can accurately predict the age at onset of MCI and AD.